首页 | 本学科首页   官方微博 | 高级检索  
检索        

琥珀散对子宫内膜异位症大鼠NO及NOS作用研究
引用本文:王素霞,张丽霞.琥珀散对子宫内膜异位症大鼠NO及NOS作用研究[J].中医药学刊,2010(7):1430-1432.
作者姓名:王素霞  张丽霞
作者单位:[1]杭州市中医院中医妇科,浙江杭州310007 [2]杭州市拱墅区中医院,浙江杭州310005
基金项目:浙江省中医药管理局立项课题(2006C185)
摘    要:目的:探讨琥珀散治疗子宫内膜异位症(EMs)的作用机理。方法:采用夹尾刺激加自体子宫内膜移植法建立病证结合的气滞血瘀型EMs大鼠模型。随机分为模型组、治疗组(琥珀散高剂量组、琥珀散中剂量组、琥珀散低剂量组)和孕三烯酮组,分别灌胃给药,4周后处死。比色法检测血清一氧化氮(NO)含量和一氧化氮合酶(NOS)活性,酶联免疫法检测血浆前列腺素2α(PGF2α)水平,光镜下观察子宫内膜形态学变化。结果:①琥珀散高、中剂量组可降低模型鼠血清NO含量、NOS活性和血浆PGF2α水平,与模型组比较,差异均有统计学意义(P〈0.01);与孕三烯酮组相比,差异均无统计学意义(P〉0.05);琥珀散低剂量组可降低模型鼠NO含量,与模型组比较,差异有统计学意义(P〈0.05)。②模型组大鼠在位内膜腺体数量多,腺腔完整,异位内膜出现类似于在位子宫内膜的结构。治疗组大鼠在位内膜变化不明显,异位内膜体积偏小,腺体减少,腺上皮呈不同程度的萎缩。孕三烯酮组大鼠在位、异位内膜均见腺体数目少,腺腔缩小,腺上皮细胞萎缩。结论:琥珀散可以降低EMs大鼠血清NO、NOS及血浆PGF2α水平,这可能是琥珀散有效抑制异位病灶种植、生长,缓解盆腔疼痛的作用机理之一。

关 键 词:琥珀散  子宫内膜异位症(EMs)  一氧化氮(NO)一氧化氮合酶(NOS)  前列腺素2α(PGF2α)

Effect of Huposan on Nitric Oxide and Nitric Oxide Synthase in Endometriosis Rats
WANG Su-Xia,ZHANG Li-xia.Effect of Huposan on Nitric Oxide and Nitric Oxide Synthase in Endometriosis Rats[J].Study Journal of Traditional Chinese Medicine,2010(7):1430-1432.
Authors:WANG Su-Xia  ZHANG Li-xia
Institution:1.Hangzhou Hospital of TCM,Hangzhou 310007,Zhejiang,China;2.Gongshu District Hospital of TCM,Hangzhou 310005,Zhejiang,China)
Abstract:Objective: To explain the mechanism of Huposan on Endmetriosis.Methods: To creat EMs Rats of Qi stagnation and blood stasis by auto-transplanting endometrium and tail-clamped.Randomly were divided into five groups: Model group,Gestrinone group,Huposan high dose,Huposan medium dose and Huposan low dose group.All of them were treated respectively for four weeks,and then put them to death.The level of NO and NOS in the serum was detected by colorimetry,and ELISA immunohistochemical method was used to detect the level of PGF2α in the plasma.The morphous of both eutopic and ectopic endometrium was detected by light microscope.Results:①HuPoSan can reduce the level of NO and NOS in the serum of model rats and PGF2α in the plasma of model rats,medium dose team was similar to high dose team,and was lower to the low dose team(P〈0.01),of which the difference was significant with the model group(P〈0.01).The difference between low dose team and model group had statistics sign in content of NO(P〈0.05),was statistics significant in activity of NOS and PGF2α(P〈0.01).②There were non-statistics significant difference among the group of Gestrinone,medium dose team and high dose team on the level of NO and NOS in the serum and PGF2α in the plasma.(P〈0.05).③In the group of HuPoSan,the volume of ectopic endometrium was reduced,with glandular organ and inflammatory cell reducing and glandular epithelium atrophy in varying degree,which was similar to the group of Gestrinone and better than the model group.Conclusion: ①HuPoSan can reduce the level of NO and NOS in the serum of model rats,and then reduce the invasion,metastasis and vasiformation process of ectopic endometrium.So we suppose that it may be one of the mechanismses of HuPoSan on EMs.②The circumstance that HuPoSan can reduce the content of PGF2α in the plasma provides theoryetical and experimental foundation that HuPoSan may become a new way of treatment for pain of EMs scientificly.
Keywords:Endometriosis  HuPoSan  nitric oxide  nitric oxide synthase  prostaglandin F2α
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号